Renaissance Technologies LLC boosted its position in SIGA Technologies, Inc. (NASDAQ:SIGA – Free Report) by 404.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,936 shares of the company’s stock after purchasing an additional 74,500 shares during the period. Renaissance Technologies LLC owned approximately 0.13% of SIGA Technologies worth $705,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale acquired a new stake in shares of SIGA Technologies in the second quarter valued at $40,000. Bayesian Capital Management LP acquired a new stake in SIGA Technologies in the 1st quarter valued at about $97,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of SIGA Technologies by 38.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,684 shares of the company’s stock valued at $104,000 after purchasing an additional 3,829 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of SIGA Technologies in the 1st quarter worth approximately $105,000. Finally, EntryPoint Capital LLC bought a new stake in shares of SIGA Technologies in the 1st quarter worth approximately $111,000. 55.40% of the stock is owned by institutional investors.
SIGA Technologies Stock Performance
Shares of NASDAQ:SIGA opened at $6.67 on Wednesday. The stock has a market capitalization of $474.39 million, a price-to-earnings ratio of 6.25 and a beta of 0.90. SIGA Technologies, Inc. has a 1-year low of $4.26 and a 1-year high of $12.83. The company has a 50 day moving average price of $8.49 and a 200 day moving average price of $8.37.
About SIGA Technologies
SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Further Reading
- Five stocks we like better than SIGA Technologies
- How to Find Undervalued Stocks
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What is an Earnings Surprise?
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- The 3 Best Blue-Chip Stocks to Buy Now
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.